Process Improvement for Maximized Therapeutic Innovation Outcome

Scott A. Waldman, Andre Terzic

Research output: Contribution to journalEditorial

1 Citation (Scopus)

Abstract

Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.

Original languageEnglish (US)
Pages (from-to)8-12
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume103
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Parity
Health
Therapeutics
Population

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Process Improvement for Maximized Therapeutic Innovation Outcome. / Waldman, Scott A.; Terzic, Andre.

In: Clinical Pharmacology and Therapeutics, Vol. 103, No. 1, 01.01.2018, p. 8-12.

Research output: Contribution to journalEditorial

@article{594cbad1d72845a785fc0b773d07302c,
title = "Process Improvement for Maximized Therapeutic Innovation Outcome",
abstract = "Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.",
author = "Waldman, {Scott A.} and Andre Terzic",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.929",
language = "English (US)",
volume = "103",
pages = "8--12",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Process Improvement for Maximized Therapeutic Innovation Outcome

AU - Waldman, Scott A.

AU - Terzic, Andre

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.

AB - Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.

UR - http://www.scopus.com/inward/record.url?scp=85038370302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038370302&partnerID=8YFLogxK

U2 - 10.1002/cpt.929

DO - 10.1002/cpt.929

M3 - Editorial

VL - 103

SP - 8

EP - 12

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -